ArticleDiabetes/metabolism research and reviews2025
Development of a Chinese-Specific Clinical Model to Predict Maturity-Onset Diabetes of the Young.
Article in Diabetes/metabolism research and reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Identification of maturity-onset diabetes of the young through targeted next-generation sequencing in Thai patients with atypical diabetes in real-world practice.Frontiers in endocrinology · 2026Article
- Prediction of maturity-onset diabetes of the young subtypes using machine learning.Frontiers in digital health · 2026Article
- Development of a Chinese-Specific Clinical Model to Predict Maturity-Onset Diabetes of the Young.Diabetes/metabolism research and reviews · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
aimsAccurate identification of individuals with maturity-onset diabetes of the young (MODY) can support precision diabetes management. However, diagnosing MODY is challenging due to overlapping clinical features with type 2 diabetes. We aimed to develop a prediction model for identifying Chinese with high likelihood of MODY for further genetic testing.
methodsWe developed a logistic regression model using clinical data from an unselected cohort of 1021 Chinese with young-onset (age at diagnosis ≤ 40) non-type 1 diabetes enrolled in the Hong Kong Diabetes Register, 1.9% (n = 19) of whom had MODY (GCK-, HNF1A-, HNF4A- and HNF1B-MODY) by molecular confirmation. We validated the model in an independent local cohort of 822 Chinese with young-onset non-type 1 diabetes. We compared the performance of the new Chinese-specific MODY prediction model with an existing MODY probability calculator in the validation cohort.
resultsThe prediction model comprised the following clinical variables: current age, age at diagnosis, sex, body mass index, systolic blood pressure, HDL-cholesterol, LDL-cholesterol, triglyceride and fasting C-peptide. It demonstrated acceptable discrimination of patients with MODY in the validation dataset, with an area under the curve of 0.813 (95% confidence interval 0.647-0.979). At the probability cut-off of 50%, the model achieved a sensitivity of 72.7% and a specificity of 92.4%. It allows identification of one MODY case in every nine genetic tests conducted.
conclusionWe developed a comprehensive Chinese-specific MODY prediction model. This model can be used in unselected Chinese with young-onset non-type 1 diabetes to identify high-risk individuals for genetic testing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.